While exact copies of Ozempic and Wegovy will no longer be allowed, compounders may still create modified versions if they change the dosage, add other ingredients, or alter the method of administration in compliance with FDA regulations, Fortune reported. "FDA confirmed with the drug's manufacturer that their stated product availability and manufacturing capacity can meet the present and projected national demand," the agency said. However, it warned of potential "intermittent and limited localized supply disruptions" as inventory moves through the supply chain. Compounding pharmacies and brand-name GLP-1 manufacturers have long debated the safety and necessity of compounded versions. Drugmakers argue the medications are too complex to safely replicate, while compounders have defended their quality and expressed skepticism about drugmakers' ability to keep up with demand.